Fig. 2: Treatment patterns per line of treatment. | Blood Cancer Journal

Fig. 2: Treatment patterns per line of treatment.

From: Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis

Fig. 2

Proportion of patients with treatment regimen by risk subgroup (A), and Sankey plots showing treatment patterns for first-line (B), second-line (C), and third-line (D) treatment. An asterisk symbol represents all other therapies, where < 1% of patients receive a particular treatment regimen. The overall number across each line of therapy includes those patients with undocumented risk who were not included in the analyses. Therefore, the N indicated here is the sum of the t(11;14)+, high-risk and standard-risk subgroups, so does not equal the total number of patients. C cyclophosphamide, d dexamethasone, D daratumumab, E elotuzumab, I ixazomib, K carfilzomib, M melphalan, P pomalidomide, PLD pegylated liposomal doxorubicin, R lenalidomide, t translocation, V bortezomib.

Back to article page